-
Jul 2, 2024 | 
medscape.com | Benjamin L. Schlechter |J. Joshua Smith
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer. Today we're discussing nonoperative management of rectal cancer with our guest, Dr Joshua Smith.
-
Jun 13, 2024 | 
nature.com | Andrea Bullock |Benjamin L. Schlechter |Marwan Fakih |Joseph E. Grossman |Rachel E. Sanborn |Bruno Bockorny | +3 more
AbstractMicrosatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.
-
Jun 5, 2024 | 
medscape.com | Benjamin L. Schlechter |Cathy Eng
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer. Today we're discussing treatment options for refractory colorectal cancer with Dr Cathy Eng.
-
May 1, 2024 | 
medscape.com | Benjamin L. Schlechter |Kimmie Ng
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer.
-
May 1, 2024 | 
medscape.com | Benjamin L. Schlechter |Pashtoon M. Kasi
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter and welcome to Medscape's InDiscussion series on colorectal cancer. Today, we're discussing circulating tumor DNA (ctDNA) and colorectal cancer with Dr Pashtoon Kasi.
-
May 1, 2024 | 
jitc.bmj.com | Benjamin L. Schlechter |Justin Stebbing
Colon Cancer Immune Checkpoint Inhibitor Tumor microenvironment - TME Cytokine The C-C motif chemokine receptor and ligand type 5 (CCR5 and CCL5, respectively) axis is a well-described pathway in immune regulation famously associated with HIV-1 resistance due to mutations that inhibit viral infection and has emerged as a therapeutic target in the fight against AIDS.1 CCR5 is a cell surface receptor that is expressed on various immune cells while CCL5 is a chemokine that interacts with CCR5 to...
-
Sep 6, 2023 | 
medscape.com | Benjamin L. Schlechter |Ammar Sarwar
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin Schlechter, MD: Hello. I'm Dr Benjamin Schlechter. Welcome to Medscape's InDiscussion series on colorectal cancer. Today we're discussing liver-directed therapy for colorectal cancer with Dr Ammar Sarwar.
-
Aug 1, 2023 | 
medscape.com | Benjamin L. Schlechter |John Strickler
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter, and welcome to Medscape's InDiscussion series on colorectal cancer.
-
Jun 9, 2023 | 
onclive.com | Benjamin L. Schlechter
Benjamin L. Schlechter, MD, senior physician, Dana-Farber Cancer Institute, instructor, medicine, Harvard Medical School, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors. The ongoing, phase 1/2 TACTIC-2 trial (NCT04727151) is evaluating the efficacy and safety of autologous TAC01-HER2 T-cell therapy in patients with HER2-positive breast, colorectal, gall bladder, gastroesophageal junction (GEJ), gastric, esophageal, lung, and ovarian cancers.
-
Jun 1, 2023 | 
medscape.com | Benjamin L. Schlechter |Marwan Fakih
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter and welcome to Medscape's InDiscussion series on colorectal cancer.
